Skip to main content
Premium Trial:

Request an Annual Quote

Profos Raises $6.1M to Develop, Market Bacterial Detection Based on Phage Ligand Technology

NEW YORK, Aug. 24 (GenomeWeb News) - Profos of Regensburg, Germany, has raised €5 million ($6.1 million) in venture capital to develop and market new products for the capture and detection of bacteria and endotoxins, the company said yesterday.

 

Profos has been developing its phage-ligand technology for two applications in pathogen testing for food safety and for the detection and removal of bacterial endotoxins during the manufacture of biopharmaceutical drugs.

 

The funding came from lead investor Bio Fund Management of Helsinki, Finland, and from two existing shareholders, Danisco Venture of Copenhagen, Denmark, and Capital Stage of Hamburg, Germany.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.